@article{cbe0f25498954c9a8eeb444085c06816,
title = "Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia",
abstract = "Patients with chronic lymphocytic leukaemia (CLL) disease progression on ibrutinib or after sequential ibrutinib and venetoclax-based treatments (double-refractory) have poor outcomes. In this retrospective study, we analysed outcomes with combined ibrutinib and venetoclax treatment in these groups of patients. The median treatment-free and overall survival for 22 patients with prior progression on ibrutinib (venetoclax-na{\"i}ve) were 23.7 and 47.1 months respectively. In 11 patients with double-refractory CLL, the median treatment-free and overall survival were 11.2 and 27.0 months respectively. The combination of ibrutinib and venetoclax may help bridge the current gap in options for patients with disease refractory to the most commonly used novel agents.",
keywords = "chronic lymphocytic leukaemia, ibrutinib, treatment, venetoclax",
author = "Hampel, {Paul J.} and Rabe, {Kari G.} and Call, {Timothy G.} and Wei Ding and Leis, {Jose F.} and Kenderian, {Saad S.} and Eli Muchtar and Yucai Wang and Koehler, {Amber B.} and Ricardo Parrondo and Schwager, {Susan M.} and Min Shi and Esteban Braggio and Slager, {Susan L.} and Kay, {Neil E.} and Parikh, {Sameer A.}",
note = "Funding Information: The conduct of this research was supported by the Henry J. Predolin Foundation. Funding Information: Paul J. Hampel, Kari G. Rabe, Timothy G. Call, Jose F. Leis, Ricardo Parrondo, Susan M. Schwager, Min Shi, Esteban Braggio, and Susan L. Slager: none. Wei Ding: research funding has been provided to the institution from Merck and DTRM. Participation in advisory board meetings for Merck and Octapharma. Saad S. Kenderian: consultancy, honoraria, and research funding from Humanigen, Inc. Eli Muchtar: honorarium from Janssen. Consultation fee from Protego (paid to the institution). Yucai Wang: membership on Board of Directors or advisory committee for Incyte, LOXO Oncology, Eli Lilly, TG Therapeutics, InnoCare, Kite. Research funding from Incyte, InnoCare, LOXO Oncology, Novartis, Genentech, MorphoSys. Amber B. Koehler: membership on Board of Directors or advisory committees for AbbVie and TG Therapeutics. Neil E. Kay: membership on Board of Directors or advisory committees for Abbvie, BMS, Celgene, Pharmacyclics, AstraZeneca, Behring, CytomX Therapeutics, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Targeted Oncology, Agios Pharm, Morpho‐sys, Rigel. Research funding from Abbvie, Acerta Pharma, BMS, Celgene, Genentech, MEI Pharma, Sunesis, TG Therapeutics, Tolero Pharmaceuticals. Sameer A. Parikh: research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which Sameer A. Parikh is a principal investigator. Sameer A. Parikh has received honoraria for participation in consulting activities/advisory board meetings for Pharmacyclics, Merck, AstraZeneca, Genentech, GlaxoSmithKline, Adaptive Biotechnologies, Amgen, and AbbVie (no personal compensation); and from DynaMed, Aptitude Health, Curio Science, and MedEd on the Go (with personal compensation). Publisher Copyright: {\textcopyright} 2022 British Society for Haematology and John Wiley & Sons Ltd.",
year = "2022",
month = oct,
doi = "10.1111/bjh.18357",
language = "English (US)",
volume = "199",
pages = "239--244",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",
}